PDS BIOTECHNOLOGY CORP.

Lars Boesgaard submitted his resignation as CFO effective September 12, 2026; his departure is not related to any disagreements over the company’s business operations. The board appointed Janetta Trochimiuk as acting head of accounting and CEO Dr. Frank Bedu-Addo as acting chief financial officer, both positions effective September 12, 2026. Trochimiuk will retain her current base salary and remain eligible under the existing equity incentive plan; no new equity awards were granted. At the annual general meeting, shareholders approved increasing the number of authorized common shares from 150 million to 300 million. » Más en de.investing.com

Shareholders of PDS Biotechnology approved an amendment to increase the authorized common shares from 150 million to 300 million; the vote was 19,904,111 in favor and 11,545,436 against. At the annual meeting, where roughly 56.6% of outstanding shares were represented, Kamil Ali-Jackson and Ilian Iliev were elected as Class B directors. Shareholders also ratified KPMG US LLP as the independent registered public accounting firm for fiscal 2026 and approved a non-binding, advisory say-on-pay vote. » Más en de.investing.com

PDS Biotechnology reported Q1 2026 EPS of -$0.13, beating the analyst expectation of -$0.15. The company cut R&D expenses by 39.7% and reduced the net loss to $7.3 million, while cash and cash equivalents stood at $21.7 million. Strategic adjustments to the VERSATILE‑003 study are intended to accelerate the approval process; despite improvements, losses are still expected in coming quarters. The stock rose 6.36% in premarket trading on positive investor reaction. » Más en de.investing.com